About BioMarin Pharmaceutical Inc.
https://www.biomarin.comBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
CEO
Alexander Hardy
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 265
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Truist Securities
Buy
Guggenheim
Buy
UBS
Buy
Goldman Sachs
Buy
B of A Securities
Buy
Bernstein
Outperform
Grade Summary
Showing Top 6 of 19
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:22.74M
Value:$1.28B
BLACKROCK, INC.
Shares:22.05M
Value:$1.24B
VANGUARD GROUP INC
Shares:18.58M
Value:$1.04B
Summary
Showing Top 3 of 805
About BioMarin Pharmaceutical Inc.
https://www.biomarin.comBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $776.13M ▼ | $682.74M ▲ | $-30.74M ▼ | -3.96% ▼ | $-0.16 ▼ | $-5.26M ▼ |
| Q2-2025 | $825.41M ▲ | $398.43M ▲ | $240.53M ▲ | 29.14% ▲ | $1.25 ▲ | $319.11M ▲ |
| Q1-2025 | $745.14M ▼ | $369.69M ▼ | $185.69M ▲ | 24.92% ▲ | $0.97 ▲ | $263.02M ▲ |
| Q4-2024 | $747.31M ▲ | $449.77M ▲ | $124.94M ▲ | 16.72% ▲ | $0.66 ▲ | $195.5M ▲ |
| Q3-2024 | $745.74M | $443.39M | $106.08M | 14.22% | $0.57 | $156.41M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.48B ▲ | $7.61B ▲ | $1.56B ▲ | $6.06B ▲ |
| Q2-2025 | $1.43B ▲ | $7.46B ▲ | $1.43B ▲ | $6.03B ▲ |
| Q1-2025 | $1.27B ▲ | $7.15B ▲ | $1.35B ▲ | $5.79B ▲ |
| Q4-2024 | $1.14B ▲ | $6.99B ▲ | $1.33B ▼ | $5.66B ▲ |
| Q3-2024 | $930.44M | $6.85B | $1.44B | $5.41B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-30.74M ▼ | $368.69M ▲ | $-330.96M ▼ | $-2.17M ▲ | $36.29M ▼ | $340.24M ▲ |
| Q2-2025 | $426.22M ▲ | $185.27M ▲ | $-12.59M ▲ | $-4.6M ▲ | $165.01M ▲ | $168.17M ▲ |
| Q1-2025 | $185.69M ▲ | $174.39M ▼ | $-28.24M ▼ | $-38.78M ▼ | $105.96M ▼ | $157.63M ▼ |
| Q4-2024 | $124.94M ▲ | $185.63M ▼ | $76.4M ▲ | $2.86M ▲ | $267.39M ▲ | $165.33M ▼ |
| Q3-2024 | $106.08M | $221.48M | $-16.16M | $-499.13M | $-296.7M | $200.31M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $740.00M ▲ | $730.00M ▼ | $810.00M ▲ | $760.00M ▼ |
 Royalty And Other | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $20.00M ▲ |
Revenue by Geography
| Region | Q4-2020 | Q1-2021 | Q3-2021 | Q2-2021 |
|---|---|---|---|---|
 Europe | $140.00M ▲ | $160.00M ▲ | $120.00M ▼ | $170.00M ▲ |
 Latin America | $60.00M ▲ | $60.00M ▲ | $40.00M ▼ | $40.00M ▲ |
 Rest of World | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ | $80.00M ▲ |
 UNITED STATES | $180.00M ▲ | $210.00M ▲ | $200.00M ▼ | $200.00M ▲ |
CEO
Alexander Hardy
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 265
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Truist Securities
Buy
Guggenheim
Buy
UBS
Buy
Goldman Sachs
Buy
B of A Securities
Buy
Bernstein
Outperform
Grade Summary
Showing Top 6 of 19
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:22.74M
Value:$1.28B
BLACKROCK, INC.
Shares:22.05M
Value:$1.24B
VANGUARD GROUP INC
Shares:18.58M
Value:$1.04B
Summary
Showing Top 3 of 805